I vividly recall the excitement on the faces of thousands of physicians attending the AAAAI meeting back in 1986 where for the first time the significance of IL5 was being introduced to the allergy arena. Now we are using Nucala: mepolizumab; anti-interleukin [IL]-5 on select patients. New biologicals are the key to success